Jaap J Boelens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8250075/publications.pdf

Version: 2024-02-01

337 papers	11,720 citations	25423 59 h-index	40945 97 g-index
352 all docs	352 docs citations	352 times ranked	12493 citing authors

#	Article	IF	Citations
1	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain, 2022, 145, 105-118.	3.7	18
2	B-cell depletion abrogates immune mediated cytopenia and rejection of cord blood transplantation in Hurler syndrome. Bone Marrow Transplantation, 2022, 57, 38-42.	1.3	5
3	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics Journal, 2022, 22, 9-18.	0.9	1
4	Antithymocyte globulin exposure in CD34+ T-cellâ€“depleted allogeneic hematopoietic cell transplantation. Blood Advances, 2022, 6, 1054-1063.	2.5	12
5	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 2022, 6, 1961-1968.	2.5	47
6	Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: anÂeffective, low toxicity, TBI-free conditioning regimen. Blood Advances, 2022, 6, 1719-1730.	2.5	8
7	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2022, 28, 72.e1-72.e8.	0.6	21
8	Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. Blood Advances, 2022, 6, 1512-1524.	2.5	11
9	Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. Clinical Pharmacokinetics, 2022, 61, 553-563.	1.6	5
10	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 196-202.	0.6	12
11	Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. Cytotherapy, 2022, 24, 428-436.	0.3	2
12	Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. Blood, 2022, 139, 2758-2769.	0.6	25
13	Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematology,the, 2022, 9, e111-e120.	2.2	25
14	Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 337-340.	0.6	16
15	Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi). Orphanet Journal of Rare Diseases, 2022, 17, 48.	1.2	10
16	Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept. Frontiers in Pharmacology, 2022, 13, 828094.	1.6	9
17	Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates. Science Translational Medicine, 2022, 14, eabm8646.	5.8	6
18	Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2022, 24, 249-261.	0.3	9

#	Article	IF	Citations
19	Encouraging Outcomes after Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients. Transplantation and Cellular Therapy, 2022, 28, S434-S435.	0.6	0
20	An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. Cytotherapy, 2022, 24, 385-392.	0.3	2
21	Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. Cytotherapy, 2022, 24, 884-891.	0.3	3
22	Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, 530-545.	0.6	12
23	CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. Blood, 2021, 137, 848-855.	0.6	27
24	Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome. Transplantation and Cellular Therapy, 2021, 27, 91.e1-91.e4.	0.6	6
25	Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens. Bone Marrow Transplantation, 2021, 56, 1426-1432.	1.3	7
26	Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. Bone Marrow Transplantation, 2021, 56, 1238-1247.	1.3	9
27	Harmonization, biomarkers, disease risk index. Blood, 2021, 137, 874-875.	0.6	0
28	Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients. British Journal of Clinical Pharmacology, 2021, 87, 3218-3226.	1.1	4
29	Persistent or New Cytopenias Are a Better Predictor of Relapse Than Routine Bone Marrow Aspirate Evaluations after Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Pediatric and Young Adult Patients. Transplantation and Cellular Therapy, 2021, 27, S137-S139.	0.6	0
30	A Minimal Parameter Set Facilitating Early Decision-making in the Diagnosis of Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2021, 41, 1219-1228.	2.0	8
31	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Cerebral Adrenoleukodystrophy: Effects of Donor Cell Source and Match, Conditioning Regimen, and Stage of Cerebral Disease. Transplantation and Cellular Therapy, 2021, 27, S318-S319.	0.6	0
32	New insights in phenotype and treatment of lung disease immuno-deficiency and chromosome breakage syndrome (LICS). Orphanet Journal of Rare Diseases, 2021, 16, 137.	1.2	3
33	The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury. Blood, 2021, 137, 1679-1689.	0.6	18
34	Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma. Cancers, 2021, 13, 2096.	1.7	12
35	Efficient lentiviral transduction method to gene modify cord blood CD8+ TÂcells for cancer therapy applications. Molecular Therapy - Methods and Clinical Development, 2021, 21, 357-368.	1.8	6
36	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 2826-2833.	1.3	5

#	Article	IF	Citations
37	Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT. Bone Marrow Transplantation, 2021, 56, 2697-2704.	1.3	2
38	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	0.6	65
39	Long-term effect of hematopoietic cell transplantation on systemic inflammation in patients with mucopolysaccharidoses. Blood Advances, 2021, 5, 3092-3101.	2.5	2
40	Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) â€“ Case series. Molecular Genetics and Metabolism Reports, 2021, 28, 100779.	0.4	1
41	Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes. Transplantation and Cellular Therapy, 2021, 27, 780.e1-780.e14.	0.6	6
42	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	4
43	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	0.6	4
44	Î±Î² T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Advances, 2021, 5, 240-249.	2.5	21
45	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplantation and Cellular Therapy, 2021, 28, 101.e1-101.e1.	0.6	7
46	Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. New England Journal of Medicine, 2021, 385, 1929-1940.	13.9	75
47	A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. Clinical Immunology, 2020, 212, 108248.	1.4	15
48	Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children. Biology of Blood and Marrow Transplantation, 2020, 26, 114-122.	2.0	18
49	A â€œNoâ€Touchâ€•Antibodyâ€Staining Method of Adherent Cells for Highâ€Throughput Flow Cytometry in 384â€Well Microplate Format for Cellâ€Based Drug Library Screening. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 845-851.	1.1	3
50	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
51	Longitudinal Analysis of Ocular Disease in Children with Mucopolysaccharidosis I after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 928-935.	2.0	6
52	Clinical Grade Production of Wilmsâ€™ Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation. Frontiers in Immunology, 2020, 11, 559152.	2.2	9
53	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. Cytotherapy, 2020, 22, 474-481.	0.3	29
54	Transplant- and Disease-Related Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Cerebral Adrenoleukodystrophy Vary By Donor Cell Source, Conditioning Regimen, and Stage of Cerebral Disease. Biology of Blood and Marrow Transplantation, 2020, 26, S211.	2.0	0

#	Article	IF	Citations
55	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biology of Blood and Marrow Transplantation, 2020, 26, e235-e236.	2.0	0
56	Metachromatic leukodystrophy genotypes in The Netherlands reveal novel pathogenic ARSA variants in non-Caucasian patients. Neurogenetics, 2020, 21, 289-299.	0.7	9
57	Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization. Frontiers in Pediatrics, 2020, 8, 454.	0.9	8
58	Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. Cytotherapy, 2020, 22, 503-510.	0.3	27
59	Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile. Bone Marrow Transplantation, 2020, 55, 2188-2192.	1.3	9
60	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 2160-2169.	1.3	11
61	Towards new long-term composite â€˜Quality of Survivalâ€™ endpoints. Bone Marrow Transplantation, 2020, 55, 1898-1899.	1.3	0
62	Anti-thymocyte globulin for GVHD: one dose does not fit all. Lancet Haematology,the, 2020, 7, e505.	2.2	4
63	Early CD4+ T-Cell Reconstitution Is an Excellent Predictor for Survival and Non-Relapse Mortality in Pediatric and Young Adult Patients Who Develop Moderate to Severe Acute Graft-Versus-Host-Disease; A Dual Center Validation. Biology of Blood and Marrow Transplantation, 2020, 26, S188-S189.	2.0	2
64	Time-Driven Activity-Based Costing (TDBAC) Identifies Time and Effort Required for Completion of CIBMTR Forms and Can Assist in Resource Planning for HCT Centers. Biology of Blood and Marrow Transplantation, 2020, 26, S254.	2.0	0
65	Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell. Biology of Blood and Marrow Transplantation, 2020, 26, S157.	2.0	1
66	Hearing loss in patients with mucopolysaccharidoses â€1 and â€6 after hematopoietic cell transplantation: A longitudinal analysis. Journal of Inherited Metabolic Disease, 2020, 43, 1279-1287.	1.7	5
67	Hurdles in treating Hurler disease: potential routes to achieve a â€œrealâ€•cure. Blood Advances, 2020, 4, 2837-2849.	2.5	8
68	Early CD4+ T Cell Reconstruction As Predictor for Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients: A Validation Cohort Analyses. Biology of Blood and Marrow Transplantation, 2020, 26, S302-S303.	2.0	4
69	Prospective Open-Label Phase II Trial of Individualized Anti-Thymocyte Globulin for Improved T-Cell Reconstitution after Pediatric Allogeneic Hematopoietic Cell Transplantation: The Parachute-Study. Biology of Blood and Marrow Transplantation, 2020, 26, S33-S34.	2.0	7
70	A semiâ€•mechanistic model based on glutathione depletion to describe intraâ€•individual reduction in busulfan clearance. British Journal of Clinical Pharmacology, 2020, 86, 1499-1509.	1.1	18
71	Durable Remission Following â€œOff-the-Shelfâ€•Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, S89.	2.0	13
72	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplantation, 2020, 55, 1093-1102.	1.3	78

#	Article	IF	Citations
73	Metachromatic leukodystrophy and transplantation: remyelination, no crossâ€correction. Annals of Clinical and Translational Neurology, 2020, 7, 169-180.	1.7	45
74	Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 272-281.	1.3	6
75	Rabbit Anti-Thymocyte Globulin (ATG) Exposure after Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation Is Highly Variable and Impacts Immune Reconstitution in Pediatric and Young Adult Patients. Biology of Blood and Marrow Transplantation, 2020, 26, S155.	2.0	0
76	Combining Clofarabine/Fludarabine with Exposure Targeted Busulfan for Pediatric Leukemia Is an Effective, Low Toxic TBI-Free Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2020, 26, S34.	2.0	0
77	Timing of Induction Treatment for Reactivation of Cytomegalovirus Impacts Overall Survival in Pediatric Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, S347.	2.0	1
78	Comparison of Fixed Vs ALC-Based Doses of ThymoglobulinÂ® (ATG) in Pediatric Patients with Acute Leukemia Given Î±Î²haplo-HSCT: Impact on Immune Reconstitution at Day 90. Blood, 2020, 136, 16-16.	0.6	0
79	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. Blood, 2020, 136, 30-31.	0.6	0
80	Pharmacotherapy in Pediatric Hematopoietic Cell Transplantation. Handbook of Experimental Pharmacology, 2019, 261, 471-489.	0.9	1
81	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biology of Blood and Marrow Transplantation, 2019, 25, 1890-1897.	2.0	19
82	Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Orphanet Journal of Rare Diseases, 2019, 14, 240.	1.2	54
83	Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. Frontiers in Pediatrics, 2019, 7, 433.	0.9	68
84	Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. Clinical Pharmacokinetics, 2019, 58, 1609-1620.	1.6	27
85	Metatranscriptomic Evaluation of Pulmonary Complications after Pediatric Hematopoietic Cell Transplantation Reveals Pathogenic Microbes Linked to Dysregulated Human Immunologic Gene Expression. Biology of Blood and Marrow Transplantation, 2019, 25, S45.	2.0	0
86	Predictors of Donor/Host (D/H) Lineage Specific Chimerism Trends in Pediatric Patients Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S219.	2.0	0
87	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. Journal of Allergy and Clinical Immunology, 2019, 143, 2238-2253.	1.5	60
88	Adequate CD4+ T Cell Reconstitution Prior to Onset of Agvhd Grade II-IV Protects Against Transplantation Related Mortality. Biology of Blood and Marrow Transplantation, 2019, 25, S227-S228.	2.0	0
89	Longitudinal Analysis of the Effect of Hematopoietic Cell Transplantation on Ocular Disease in Children with Mucopolysaccharidosis I Shows Ongoing Disease Progression. Biology of Blood and Marrow Transplantation, 2019, 25, S41-S42.	2.0	0
90	Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients. Rheumatology, 2019, 58, 1812-1817.	0.9	11

#	Article	IF	Citations
91	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Journal of Clinical Oncology, 2019, 37, 367-374.	0.8	110
92	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1526-1535.	2.0	15
93	Retrospective Review of Use of Individualized Dosing of Rabbit Anti-Thymocyte Globulin on Outcomes in Pediatric Post Allogeneic Stem Cell Transplant Patients: A Single Center Experience. Biology of Blood and Marrow Transplantation, 2019, 25, S196-S197.	2.0	0
94	Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors. Cancers, 2019, 11, 181.	1.7	16
95	Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S55.	2.0	2
96	Conditioning Prior to CAR T Cells Predicts Response and Survival in Pediatric/Young Adult Relapse/Refractory (R/R) B-ALL. Biology of Blood and Marrow Transplantation, 2019, 25, S170.	2.0	2
97	Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2019, 25, e226-e246.	2.0	110
98	Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Cerebral Adrenoleukodystrophy (CALD): Results from an Ongoing, Large, Multicenter, Observational Study. Biology of Blood and Marrow Transplantation, 2019, 25, S312.	2.0	0
99	The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Advances, 2019, 3, 1118-1128.	2.5	42
100	Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Advances, 2019, 3, 2179-2187.	2.5	42
101	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	2.5	37
102	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood, 2019, 134, 2361-2368.	0.6	190
103	Related and unrelated donor transplantation for Î²-thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	2.5	48
104	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, 488-495.	2.0	21
105	Combined haploidentical and umbilical cord blood transplantation for severe aplastic anemia: Unique hematopoietic reconstitution. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 119-123.	0.6	0
106	Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. American Journal of Transplantation, 2019, 19, 1798-1805.	2.6	9
107	Allogeneic Haematopoietic Cell Transplantation for Epidermolysis Bullosa: the Dutch Experience. Acta Dermato-Venereologica, 2019, 99, 347-348.	0.6	9
108	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2019, 184, 397-404.	1.2	10

#	Article	IF	Citations
109	Tyrosine kinase inhibitor levels matter in treating chronic GVHD. Bone Marrow Transplantation, 2019, 54, 1141-1144.	1.3	1
110	Innate Immune Recovery Predicts CD4+ T Cell Reconstitution after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 819-826.	2.0	14
111	Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Clinical Pharmacokinetics, 2019, 58, 627-637.	1.6	41
112	Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization. , 2019, , 69-74.		2
113	Pediatric primary pleural synovial sarcoma: A unique case report with brief review of literature. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 435.	0.1	0
114	Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL. Blood, 2019, 134, 4582-4582.	0.6	0
115	Towards individualized, low toxic conditioning in autologous gene-transduced hematopoietic cell transplantation. Cell & Gene Therapy Insights, 2019, 5, 1495-1503.	0.1	0
116	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial. Biology of Blood and Marrow Transplantation, 2018, 24, S57.	2.0	0
117	The Influence of Stem Cell Source on Chronic-GvHD Free, Leukemia Free Transplant Survival in Pediatric Patients with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, S113-S114.	2.0	0
118	Quality of Life of Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S29-S30.	2.0	0
119	Postâ€hematopoietic stem cell transplant hemophagocytic lymphohistiocytosis or an impostor: Case report and review of literature. Pediatric Transplantation, 2018, 22, e13174.	0.5	9
120	Diffusion tensor imaging in metachromatic leukodystrophy. Journal of Neurology, 2018, 265, 659-668.	1.8	18
121	G-CSF Treatment Further Impairs T-Cell Reconstitution in Patients with Residual Anti-Thymocyte Globulin Exposure after Hematopoietic Cell Transplantation: Implications for G-CSF Use?. Biology of Blood and Marrow Transplantation, 2018, 24, S37.	2.0	0
122	Individualized Fludarabine Dosing for Predictable Immune Reconstitution and Increased Survival Chances after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S306-S307.	2.0	1
123	Slowly Progressive Psychiatric Symptoms: ThinkÂMetachromatic Leukodystrophy. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 74-76.	0.3	17
124	Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives. Expert Review of Hematology, 2018, 11, 209-218.	1.0	5
125	Infection with a respiratory virus before hematopoietic cell transplantation is associated with alloimmune-mediated lung syndromes. Journal of Allergy and Clinical Immunology, 2018, 141, 697-703.e8.	1.5	16
126	Quantitative MR spectroscopic imaging in metachromatic leukodystrophy: value for prognosis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 105-111.	0.9	24

#	Article	IF	Citations
127	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
128	Antithymocyte Globulin: Steps Toward Individualized Dosing. Biology of Blood and Marrow Transplantation, 2018, 24, 633-634.	2.0	4
129	Relating Autoimmune Cytopenias after Hematopoietic Cell Transplantation (HCT) to Transplant-Variables and Immune Reconstitution: A Predictor Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, S183-S184.	2.0	0
130	Relating Alloimmune-Mediated Lung Complications after Hematopoietic Cell Transplantation (HCT) to Immune Reconstitution after HCT to Identify Early Predictors. Biology of Blood and Marrow Transplantation, 2018, 24, S184.	2.0	0
131	Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design. Journal of Clinical Oncology, 2018, 36, 1175-1176.	0.8	10
132	Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. Blood Advances, 2018, 2, 565-574.	2.5	19
133	Morbidity and Mortality Associated With Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplant: Too Little Defense or Harmful Immunity?. Frontiers in Microbiology, 2018, 9, 2795.	1.5	10
134	Excellent Survival Chances after Pharmacokinetic-Targeted Busulfan Plus Fludarabine and ATG for Children with Hurler Syndrome Undergoing Unrelated Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S117.	2.0	0
135	Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2018, 142, 2004-2007.	1.5	14
136	Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma. Cancer Research, 2018, 78, 6621-6631.	0.4	42
137	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Advances, 2018, 2, 1198-1206.	2.5	21
138	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Advances, 2018, 2, 49-60.	2.5	45
139	Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2018, 2, 428-432.	2.5	28
140	How to define and measure thymopoiesis after transplantation?. Bone Marrow Transplantation, 2018, 53, 1364-1365.	1.3	1
141	Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Reports, 2018, 23, 3946-3959.e6.	2.9	245
142	Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. Frontiers in Immunology, 2018, 9, 982.	2.2	11
143	Salivary Î±-Iduronidase Activity as a Potential New Biomarker for the Diagnosis and Monitoring the Effect of Therapy in Mucopolysaccharidosis Type I. Biology of Blood and Marrow Transplantation, 2018, 24, 1808-1813.	2.0	3
144	Related and Unrelated Donor Transplantation for Î² Thalassemia Major: Results of an International Survey. Blood, 2018, 132, 308-308.	0.6	1

#	Article	IF	Citations
145	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget, 2018, 9, 35611-35622.	0.8	31
146	Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease.. Journal of Clinical Oncology, 2018, 36, e15047-e15047.	0.8	0
147	First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors. Blood, 2018, 132, 2164-2164.	0.6	0
148	Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. Blood, 2018, 132, 2123-2123.	0.6	0
149	Haematopoietic stem cell transplantation for autoimmune diseases. Nature Reviews Rheumatology, 2017, 13, 244-256.	3.5	108
150	A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. Haematologica, 2017, 102, 1112-1119.	1.7	30
151	Busulfan after HSCT in children and young adults â€“ Authors' reply. Lancet Haematology,the, 2017, 4, e103-e104.	2.2	3
152	Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LCâ€“MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1055-1056, 81-85.	1.2	31
153	Incomplete biomarker response in mucopolysaccharidosis type I after successful hematopoietic cell transplantation. Molecular Genetics and Metabolism, 2017, 122, 86-91.	0.5	4
154	Innate Immune Subset Recovery is Superior after Cord Blood Compared to Bone Marrow in Pediatric Hematopoietic Cell Transplantation and Relates to Superior Survival Chances. Biology of Blood and Marrow Transplantation, 2017, 23, S164-S165.	2.0	0
155	High Exposure to Fludarabine in Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Predicts for Impaired CD4 Reconstitution and Lower Survival Chances. Biology of Blood and Marrow Transplantation, 2017, 23, S72-S73.	2.0	2
156	Haematopoietic Cell Transplant (HCT) in Pediatric Acute Myeloid Leukemia (AML) after Similar Upfront Therapy with AML-Nopho; a Comparison of Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2017, 23, S138-S139.	2.0	1
157	Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, S45-S46.	2.0	0
158	Individualized Dosing and Therapeutic Drug Monitoring (TDM) of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2017, 23, S124-S125.	2.0	1
159	Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation. Journal of Allergy and Clinical Immunology, 2017, 140, 1643-1650.e9.	1.5	87
160	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica, 2017, 102, 1291-1298.	1.7	38
161	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. Lancet Haematology,the, 2017, 4, e183-e191.	2.2	154
162	Epstein-Barr virus lymphoproliferative disease after solid organ transplantation. Cytotherapy, 2017, 19, 1270-1283.	0.3	12

#	Article	IF	Citations
163	Relationship between Mixed Donorâ€“Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 2178-2183.	2.0	74
164	Rabbit anti-human-T-lymphocyte globulinâ€”less is more. Lancet Oncology, The, 2017, 18, 996-997.	5.1	1
165	In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir. British Journal of Clinical Pharmacology, 2017, 83, 2789-2797.	1.1	11
166	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematology,the, 2017, 4, e325-e333.	2.2	72
167	Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Advances, 2017, 1, 2236-2242.	2.5	19
168	Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investigation, 2017, 4, 38-38.	1.3	40
169	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	0.8	39
170	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. Blood, 2017, 130, 847-847.	0.6	8
171	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematology,the, 2016, 3, e526-e536.	2.2	197
172	Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood, 2016, 128, 2734-2741.	0.6	144
173	Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood, 2016, 128, 2607-2615.	0.6	47
174	CD4+ Reconstitution and Event Free Survival Are Predicted By Low ATG Exposure after Cord Blood Transplantation in Children: Towards Individualized ATG Dosing to Improve Survival Chances. Biology of Blood and Marrow Transplantation, 2016, 22, S97-S98.	2.0	0
175	CD4+ T-Cell Reconstitution Strongly Predicts Viral Reactivations Associated with Complications and Mortality after Pediatric Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S300.	2.0	0
176	Cord Blood Transplantation in Chemotherapy NaÃ¯ve Patients Predisposes for Autoimmune Cytopenia in Pediatric Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S252-S253.	2.0	0
177	Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis. Bone Marrow Transplantation, 2016, 51, 1376-1378.	1.3	17
178	Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience. Blood, 2016, 127, 3098-3101.	0.6	56
179	The power of cord blood cells. Blood, 2016, 127, 3302-3303.	0.6	5
180	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biology of Blood and Marrow Transplantation, 2016, 22, 1874-1882.	2.0	78

#	Article	IF	Citations
181	Neurodevelopmental Outcome after Hematopoietic Cell Transplantation in Inborn Errors of Metabolism: Current Considerations and Future Perspectives. Neuropediatrics, 2016, 47, 285-292.	0.3	29
182	Antithymocyte globulin: Importance of good clinical pharmacological practice. Journal of Allergy and Clinical Immunology, 2016, 138, 633.	1.5	3
183	Combining Clofarabine and Fludarabine with Exposure Targeted Busulfan for Pediatric Leukemia: An Effective, Low Toxicity TBI-Free Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2016, 22, S99-S100.	2.0	2
184	Predicted Indirectly ReCognizable HLA Epitopes Class I Promote Antileukemia Responses after Cord Blood Transplantation: Indications for a Potential Novel Donor Selection Tool. Biology of Blood and Marrow Transplantation, 2016, 22, 170-173.	2.0	18
185	Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. Neurology, 2016, 87, 103-111.	1.5	40
186	Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy. Expert Opinion on Biological Therapy, 2016, 16, 801-813.	1.4	12
187	Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children. Biology of Blood and Marrow Transplantation, 2016, 22, 195-206.	2.0	76
188	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. Blood, 2016, 128, 679-679.	0.6	3
189	NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials.. Journal of Clinical Oncology, 2016, 34, 7004-7004.	0.8	3
190	Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 665-665.	0.6	0
191	Contemporary Conditioning Regimen before Allogeneic Stem Cell Transplantation for Children with Non-Malignant Diseases. Blood, 2016, 128, 3398-3398.	0.6	0
192	Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. Blood, 2016, 128, 664-664.	0.6	1
193	Predicted Indirectly Recognizable Hla Epitopes (PIRCHE) Provide a Novel Strategy to Individualize Donor Selection That Optimizes Survival Chances. Biology of Blood and Marrow Transplantation, 2015, 21, S350-S351.	2.0	0
194	Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood, 2015, 125, 2164-2172.	0.6	262
195	Health-Related Quality of Life and Perception of Care of Mucopolysaccharidosis Type I - Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation: A Parents' Perspective. Biology of Blood and Marrow Transplantation, 2015, 21, S207-S208.	2.0	0
196	Upregulation of Class I MHC on Neuroblastoma Cells By NK Cell Exposure for Enhanced CTL Reactivity. Biology of Blood and Marrow Transplantation, 2015, 21, S240.	2.0	0
197	Cognate CD4 T-Cell Licensing of Dendritic Cells Heralds Anti-Cytomegalovirus CD8 T-Cell Immunity after Human Allogeneic Umbilical Cord Blood Transplantation. Journal of Virology, 2015, 89, 1058-1069.	1.5	36
198	Respiratory Virus (RV) from Broncho Alveolar Lavage (BAL) Prior to Hematopoietic Cell Transplantation (HCT): A Strong Predictor for Allo-Immune Mediated Lung Syndromes (allo-LS). Biology of Blood and Marrow Transplantation, 2015, 21, S54-S55.	2.0	0

#	Article	IF	Citations
199	Rabbit Antiâ€“T Cell Globulin in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 959-970.	2.0	94
200	ThymoglobulinÂ® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation: Towards Individualized Dosing. Biology of Blood and Marrow Transplantation, 2015, 21, S91-S92.	2.0	0
201	Metachromatic leukodystrophy: Disease spectrum and approaches for treatment. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 261-273.	2.2	268
202	Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a crossâ€sectional national survey. Journal of Inherited Metabolic Disease, 2015, 38, 323-331.	1.7	34
203	Population Pharmacokinetic Modeling of ThymoglobulinÂ® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing. Clinical Pharmacokinetics, 2015, 54, 435-446.	1.6	79
204	Hematopoietic Cell Transplantation for Mucopolysaccharidosis Patients Is Safe and Effective: Results after Implementation of International Guidelines. Biology of Blood and Marrow Transplantation, 2015, 21, 1106-1109.	2.0	138
205	Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood, 2015, 126, 270-276.	0.6	89
206	Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1839-1845.	2.0	21
207	Umbilical cord blood: advances and opportunities. Cytotherapy, 2015, 17, 693-694.	0.3	3
208	Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2015, 135, 2319-2321.	0.3	119
209	Viral PCR Positivity in Stool before Allogeneic Hematopoietic Cell Transplantation Is Strongly Associated with Acute Intestinal Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 772-774.	2.0	16
210	Upregulation of class I MHC on neuroblastoma cells by NK cell exposure for enhanced CTL reactivity. Cytotherapy, 2015, 17, S19.	0.3	0
211	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematology,the, 2015, 2, e194-e203.	2.2	228
212	Preclinical development of cord blood-derived dendritic cell-based immunotherapies after hematopoietic cell transplantation in children with AML. Cytotherapy, 2015, 17, S9.	0.3	0
213	Hematopoietic cell transplantation does not prevent myelopathy in Xâ€linked adrenoleukodystrophy: a retrospective study. Journal of Inherited Metabolic Disease, 2015, 38, 359-361.	1.7	54
214	Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. Current Opinion in Pediatrics, 2015, 27, 9-17.	1.0	21
215	Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source?. Cytotherapy, 2015, 17, 695-701.	0.3	4
216	Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia, 2015, 29, 1839-1846.	3.3	64

#	Article	IF	Citations
217	High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children. Biology of Blood and Marrow Transplantation, 2015, 21, 1622-1626.	2.0	9
218	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	3.7	128
219	Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP. Bone Marrow Transplantation, 2015, 50, 592-597.	1.3	11
220	Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. OncoImmunology, 2015, 4, e1023973.	2.1	26
221	Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. Cytotherapy, 2015, 17, 1667-1674.	0.3	15
222	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. Biology of Blood and Marrow Transplantation, 2015, 21, 402-411.	2.0	8
223	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget, 2015, 6, 35770-35781.	0.8	37
224	Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III. JIMD Reports, 2014, 18, 63-68.	0.7	40
225	Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Archives of Disease in Childhood, 2014, 99, 267-272.	1.0	46
226	Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?. Frontiers in Immunology, 2014, 5, 218.	2.2	12
227	Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. Bone Marrow Transplantation, 2014, 49, 95-101.	1.3	45
228	Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. Pediatric Blood and Cancer, 2014, 61, 306-311.	0.8	4
229	Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. Paediatric Anaesthesia, 2014, 24, 521-527.	0.6	23
230	High-Resolution CT Can Differentiate Between Alloimmune and Nonalloimmune Lung Disease Early After Hematopoietic Cell Transplantation. American Journal of Roentgenology, 2014, 203, 656-661.	1.0	1
231	Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival. Biology of Blood and Marrow Transplantation, 2014, 20, S96-S98.	2.0	9
232	Variable Success Rates of Haplo-Cord Transplants in High Risk Patients: A Minimum Serotherapy Exposure Is a Prerequisite for Sustainable Engrafting. Biology of Blood and Marrow Transplantation, 2014, 20, S239-S240.	2.0	1
233	Prospective Validation of a Busulfan Pharmacokinetic Model in Children: Therapeutic Drug Monitoring Remains of Utmost Importance to Optimize Outcomes of HCT. Biology of Blood and Marrow Transplantation, 2014, 20, S248.	2.0	0
234	Transplantation in inborn errors of metabolism: current considerations and future perspectives. British Journal of Haematology, 2014, 167, 293-303.	1.2	60

#	Article	IF	Citations
235	A novel FcÎ³RIIa Q27W gene variant is associated with common variable immune deficiency through defective FcÎ³RIIa downstream signaling. Clinical Immunology, 2014, 155, 108-117.	1.4	15
236	Exposure of Thymoglobulin Is Associated with Overall Survival in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival. Biology of Blood and Marrow Transplantation, 2014, 20, S76-S78.	2.0	2
237	Development of a Unique Anti-AML Immune Therapy Consisting of Cord Blood HSCT and Cord Blood Stem Cell-Derived Dendritic Cell (CB-DC) Vaccination. Biology of Blood and Marrow Transplantation, 2014, 20, S133.	2.0	0
238	Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity. Biology of Blood and Marrow Transplantation, 2014, 20, 345-353.	2.0	89
239	Predictors of Long-Term Clinical Outcome in Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation: An International Study. Biology of Blood and Marrow Transplantation, 2014, 20, S78-S79.	2.0	0
240	Outcomes of Allogeneic Cord Blood Transplantation for Leukodystrophies; A Joint Study of Eurocord and "Inborn Errors WP-EBMT". Biology of Blood and Marrow Transplantation, 2014, 20, S86-S87.	2.0	0
241	Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood, 2014, 123, 126-132.	0.6	149
242	Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group. Blood, 2014, 124, 424-424.	0.6	0
243	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1608-1614.	2.0	69
244	Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science, 2013, 341, 1233158.	6.0	998
245	Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. Bone Marrow Transplantation, 2013, 48, 1460-1464.	1.3	23
246	Hemorrhagic Cystitis in a Cohort of Pediatric Transplantations: Incidence, Treatment, Outcome, and Risk Factors. Biology of Blood and Marrow Transplantation, 2013, 19, 1263-1266.	2.0	27
247	Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration. Cancer Chemotherapy and Pharmacology, 2013, 72, 1149-1155.	1.1	14
248	50-OR. Human Immunology, 2013, 74, 39.	1.2	0
249	Treatment of Steroid Resistant Grade II to IV Acute GVHD by Infusion of Mesenchymal Stroma Cells Expanded with Platelet Lysate - a Phase I/II Study. Biology of Blood and Marrow Transplantation, 2013, 19, S144.	2.0	0
250	Adenovirus PCR-Positivity in Stool Precedes Intestinal GRAFT Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, S318.	2.0	1
251	Multi-Institutional Assessments of Transplantation for Metabolic Disorders. Biology of Blood and Marrow Transplantation, 2013, 19, S58-S63.	2.0	7
252	Increased proportion of perforin-expressing CD8+T-cells indicates control of herpesvirus reactivation in children after stem cell transplantation. Clinical Immunology, 2013, 148, 92-98.	1.4	7

#	Article	IF	Citations
253	Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease. Bone Marrow Transplantation, 2013, 48, 502-507.	1.3	5
254	Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 305-313.	2.0	99
255	Development of a unique anti-AML immune therapy consisting of cord blood HSCT and cord blood stem cell-derived dendritic cell (CB-DC) vaccination. , 2013, 1, .		0
256	Functional and genetic characterization of two extremely rare cases of Williamsâ€“Beuren Syndrome associated with chronic granulomatous disease. European Journal of Human Genetics, 2013, 21, 1079-1084.	1.4	17
257	Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation. European Respiratory Journal, 2013, 41, 479-483.	3.1	0
258	Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. OncoImmunology, 2013, 2, e26403.	2.1	67
259	Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 235-240.	1.4	70
260	Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood, 2013, 121, 3981-3987.	0.6	183
261	Defects in neutrophil granule mobilization and bactericidal activity in familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) syndrome caused by STXBP2/Munc18-2 mutations. Blood, 2013, 122, 109-111.	0.6	49
262	Ocular Complications in Children Within 1 Year After Hematopoietic Stem Cell Transplantation. JAMA Ophthalmology, 2013, 131, 470.	1.4	15
263	Improvement of White Matter Changes on Neuroimaging Modalities After Stem Cell Transplant in Metachromatic Leukodystrophy. JAMA Neurology, 2013, 70, 779.	4.5	44
264	The Impact Of Thymoglobulin Prior To Pediatric Unrelated Umbilical Cord Blood Transplantation On Immune-Reconstitution and Clinical Outcome. Blood, 2013, 122, 3305-3305.	0.6	2
265	Concluding Comments and Future Directions. Pancreatic Islet Biology, 2013, , 159-166.	0.1	0
266	Hematopoietic Cell Transplantation in Inborn Errors of Metabolism. Pancreatic Islet Biology, 2013, , 37-61.	0.1	0
267	Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT. Blood, 2013, 122, 4591-4591.	0.6	3
268	Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and â€œInborn Errors WP-EBMTâ€. Blood, 2013, 122, 2101-2101.	0.6	0
269	Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults. Therapeutic Drug Monitoring, 2012, 34, 574-583.	1.0	48
270	Changing winds in refractory autoimmune disease in children. Current Opinion in Rheumatology, 2012, 24, 267-273.	2.0	11

#	Article	IF	Citations
271	Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transplantation, 2012, 47, 352-359.	1.3	65
272	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet, The, 2012, 379, 1301-1309.	6.3	324
273	First analysis of human herpesvirus 6T-cell responses: Specific boosting after HHV6 reactivation in stem cell transplantation recipients. Clinical Immunology, 2012, 144, 179-189.	1.4	12
274	FcÎ³ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood, 2012, 120, 5163-5172.	0.6	71
275	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. Clinical Pharmacokinetics, 2012, 51, 331-345.	1.6	115
276	A novel Dutch mutation in UNC13D reveals an essential role of the C2B domain in munc13â€4 function. Pediatric Blood and Cancer, 2012, 58, 598-605.	0.8	7
277	Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Severe Phenotype Hurler Syndrome: an International Multi-Center Study. Blood, 2012, 120, 1958-1958.	0.6	0
278	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. Blood, 2012, 120, 736-736.	0.6	0
279	Does high-resolution CT has diagnostic value in patients presenting with respiratory symptoms after hematopoietic stem cell transplantation?. European Journal of Radiology, 2011, 80, e536-e543.	1.2	6
280	Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia. Antiviral Therapy, 2011, 16, 611-614.	0.6	35
281	X-ALD: centralize care in an international network. Blood, 2011, 118, 1716-1717.	0.6	2
282	Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clinical and Experimental Immunology, 2011, 165, 8-18.	1.1	38
283	Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet Journal of Rare Diseases, 2011, 6, 55.	1.2	194
284	Familial Hemophagocytic Lymphohistiocytosis in a Pediatric Patient Diagnosed by Brain Magnetic Resonance Imaging. Neuropediatrics, 2011, 42, 191-193.	0.3	6
285	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. Blood, 2011, 118, 3046-3046.	0.6	0
286	298 Cd3+Cd4+-Lymphocytes as Biomarker Predicting the Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients. Pediatric Research, 2010, 68, 153-153.	1.1	0
287	How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood, 2010, 116, 5476-5485.	0.6	201
288	Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood, 2010, 116, 2635-2643.	0.6	108

#	Article	IF	Citations
289	Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders. Pediatric Clinics of North America, 2010, 57, 123-145.	0.9	111
290	Chromosomally Integrated Human Herpesvirus 6: Transmission via Cord Blood-Derived Unrelated Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 130-132.	2.0	16
291	Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes. Biology of Blood and Marrow Transplantation, 2010, 16, 782-791.	2.0	100
292	Dried Blood Spot Analysis: An Easy and Reliable Tool to Monitor the Biochemical Effect of Hematopoietic Stem Cell Transplantation in Hurler Syndrome Patients. Biology of Blood and Marrow Transplantation, 2010, 16, 701-704.	2.0	4
293	Adenovirus DNA Positivity in Nasopharyngeal Aspirate Preceding Hematopoietic Stem Cell Transplantation: A Very Strong Risk Factor for Adenovirus DNAemia in Pediatric Patients. Clinical Infectious Diseases, 2009, 49, 1536-1539.	2.9	29
294	Fatal hemophagocytic lymphohistiocytosis in Xâ€linked chronic granulomatous disease associated with a perforin gene variant. Pediatric Blood and Cancer, 2009, 52, 527-529.	0.8	26
295	Outcomes of transplantation of unrelated cord blood in children with malignant and non-malignant diseases: an Utrechtâ€“Prague collaborative study. Bone Marrow Transplantation, 2009, 43, 655-657.	1.3	6
296	Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 231-241.	2.0	107
297	Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation in Patients with Hurler Syndrome. Biology of Blood and Marrow Transplantation, 2009, 15, 618-625.	2.0	105
298	Bone-marrow transplantation in non-malignant disease. Lancet, The, 2009, 374, 856-858.	6.3	9
299	Musculoskeletal manifestations of lysosomal storage disorders. Annals of the Rheumatic Diseases, 2009, 68, 1659-1665.	0.5	93
300	Life-threatening human herpes virus-6 infection in early childhood: Presenting symptom of a primary immunodeficiency?. Pediatric Critical Care Medicine, 2009, 10, e16-e18.	0.2	9
301	Different NK cellâ€“activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood, 2009, 114, 4117-4127.	0.6	90
302	Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantion: Results of a Prospective Phase II/III Randomized, Multicenter Study.. Blood, 2009, 114, 653-653.	0.6	3
303	Incidence of Veno-Occlusive Disease with IV in Busulfan Children Is Higher Than Expected: Preliminary Results of the VOD-DF Trial.. Blood, 2009, 114, 3344-3344.	0.6	0
304	EBV post transplantation lymphoproliferative disease-associated pneumomediastinum in a pediatric patient with long-lasting low loads of plasma EBV-DNA positivity. Bone Marrow Transplantation, 2008, 42, 565-566.	1.3	1
305	Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. Journal of Clinical Virology, 2008, 43, 361-366.	1.6	68
306	Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 88-98.	2.0	69

#	Article	IF	Citations
307	The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 485-498.	2.0	161
308	Human Herpes Virus 6 Plasma DNA Positivity after Hematopoietic Stem Cell Transplantation in Children: an Important Risk Factor for Clinical Outcome. Biology of Blood and Marrow Transplantation, 2008, 14, 831-839.	2.0	109
309	Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2008, 14, 1385-1393.	2.0	44
310	Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica, 2008, 93, 1058-1067.	1.7	39
311	Intensive care unit mortality trends in children after hematopoietic stem cell transplantation: A meta-regression analysis*. Critical Care Medicine, 2008, 36, 2898-2904.	0.4	81
312	Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients. Therapeutic Drug Monitoring, 2008, 30, 504-510.	1.0	79
313	Recurrent and Opportunistic Infections in Children With Primary Intestinal Lymphangiectasia. Journal of Pediatric Gastroenterology and Nutrition, 2007, 44, 382-385.	0.9	31
314	Defective cytotoxic lymphocyte degranulation in syntaxin-11â€“deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood, 2007, 110, 1906-1915.	0.6	272
315	Successful cord blood transplantation in a premature and dysmature neonate of 1700â€‰g with reticular dysgenesis. Bone Marrow Transplantation, 2007, 39, 307-308.	1.3	7
316	Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplantation, 2007, 40, 225-233.	1.3	186
317	Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation for Children with Hurlerâ€™s Syndrome. An Eurocord-Duke University Collaborative Study.. Blood, 2007, 110, 5076-5076.	0.6	1
318	Defibrotide for the Treatment of Veno-Occlusive Disease Post SCT: Preliminary Results of EU Compassionate Use Program in 332 Patients Confirm Promising Activity and Manageable Toxicity.. Blood, 2007, 110, 613-613.	0.6	2
319	130-P. Human Immunology, 2006, 67, S136.	1.2	0
320	Pre-emptive granulocyte transfusions enable allogeneic hematopoietic stem cell transplantation in pediatric patients with chronic infections. Bone Marrow Transplantation, 2006, 37, 331-333.	1.3	11
321	Epsteinâ€“Barr virus-associated haemophagocytic lympho-histiocytosis after stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 709-710.	1.3	8
322	Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplantation, 2006, 38, 17-21.	1.3	92
323	Trends in haematopoietic cell transplantation for inborn errors of metabolism. Journal of Inherited Metabolic Disease, 2006, 29, 413-420.	1.7	98
324	Anakinra for flares of pyogenic arthritis in PAPA syndrome. British Journal of Rheumatology, 2005, 44, 406-408.	2.5	175

#	Article	IF	Citations
325	Results of Haematopoietic Stem Cell Transplantation (HSCT) for Hurlerâ€™s Syndrome: European Experience 1994â€“2004.. Blood, 2005, 106, 402-402.	0.6	2
326	Pre-Emptive Granulocyte Transfusions (GTX) in Pediatric Patients with a Chronic Bacterial or Fungal Infection Undergoing a Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2005, 106, 5340-5340.	0.6	0
327	Safety and Efficacy of Enzyme Replacement Therapy (ERT) in Combination with Haematopoietic Stem Cell Transplantation (HSCT) for Hurlerâ€™s Syndrome: European Experience 2003â€“2005.. Blood, 2005, 106, 5307-5307.	0.6	1
328	Breastfeeding, atopy, and asthma. Lancet, The, 2003, 361, 174-175.	6.3	21
329	Subcutaneous abscess formation around catheters induced by viable and nonviableStaphylococcus epidermidis as well as by small amounts of bacterial cell wall components. Journal of Biomedical Materials Research Part B, 2000, 50, 546-556.	3.0	35
330	Enhanced Susceptibility to Subcutaneous Abscess Formation and Persistent Infection around Catheters Is Associated with Sustained Interleukin-1Î² Levels. Infection and Immunity, 2000, 68, 1692-1695.	1.0	21
331	Interferonâ€Î³ Protects against Biomaterialâ€AssociatedStaphylococcus epidermidisInfection in Mice. Journal of Infectious Diseases, 2000, 181, 1167-1171.	1.9	38
332	Interleukin-1 Receptor Type I Gene-Deficient Mice Are Less Susceptible to Staphylococcus epidermidis Biomaterial-Associated Infection than Are Wild-Type Mice. Infection and Immunity, 2000, 68, 6924-6931.	1.0	24
333	Antibacterial activity of antibiotic-soaked polyvinylpyrrolidone-grafted silicon elastomer hydrocephalus shunts. Journal of Antimicrobial Chemotherapy, 2000, 45, 221-224.	1.3	32
334	Biomaterialâ€Associated Persistence ofStaphylococcus epidermidisin Pericatheter Macrophages. Journal of Infectious Diseases, 2000, 181, 1337-1349.	1.9	115
335	The in vitro Antimicrobial Activity of PVP-grafted Versus Conventional Silicon Elastomer CSF-shunts. Neurosurgery, 1997, 41, 736-736.	0.6	0
336	The in vitro Antimicrobial Activity of PVP-grafted Versus Conventional Silicon Elastomer CSF-shunts. Neurosurgery, 1997, 41, 736.	0.6	2
337	HSCT for inborn errors of metabolism and neurodegenerative disorders. , 0, , 192-204.		0